Echocardiography

The innovative echocardiography software platform "CAAS Qardia" by Pie Medical Imaging receives medical device certification in Japan

Retrieved on: 
Monday, April 24, 2023
CAAS, Web browser, E20, Certification, Journal, GLS, Assessment, Echocardiography, Automation, Medical imaging, Nursing, Medical device

MAASTRICHT, Netherlands, April 24, 2023 /PRNewswire/ -- Pie Medical Imaging, a global leader in cardiac imaging, announced it has received NINSHO Medical Device Certification for CAAS Qardia, their innovative echocardiography software platform.

Key Points: 
  • MAASTRICHT, Netherlands, April 24, 2023 /PRNewswire/ -- Pie Medical Imaging, a global leader in cardiac imaging, announced it has received NINSHO Medical Device Certification for CAAS Qardia, their innovative echocardiography software platform.
  • CAAS Qardia excels at myocardial strain analysis, stress-echo, diastolic function assessment, and (PISA) valve analysis.
  • René Guillaume, Managing Director of Pie Medical Imaging said: "With this certification of CAAS Qardia, an easy-to-use and accurate tool becomes available for Japanese healthcare institutions."
  • "Echocardiography Core Laboratory Validation of a Novel Vendor-Independent Web-Based Software for the Assessment of Left Ventricular Global Longitudinal Strain".

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Retrieved on: 
Monday, April 17, 2023
Moyamoya disease, Heart, NYHA, Mitral regurgitation, Suture, Diabetes, Hospital, Cardiac rehabilitation, EACTS, Echocardiography, Safety, Health status of Asian Americans, Clinical trial, Pathology, Minerva, Doctor of Philosophy, Infarction, Data, Incidence, MD, Patient, Risk, Mitral valve, WHO Global Preparedness Monitoring Board, Regulatory News Service, ISIN, Tricuspid valve, Death, Aix-en-Provence, III, Medtech, New York Heart Association Functional Classification, Urinary incontinence, Medical device, Dentistry, Medical imaging, Science

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Key Points: 
  • Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.
  • Very positive outcome at one month follow-up of the patient implanted with the Epygon mitral valve.
  • Less than 4% of patients with severe heart mitral insufficiency receive surgery, according to Affluent Medical estimates.
  • It is the only biomimetic cardiac mitral valve in development, mimicking the native mitral valve and physiological blood flow.

Veterinary Dentistry Specialists in Mt. Laurel, NJ, Adds a Veterinary Cardiologist to Team of Board-Certified Specialists in Dentistry and Anesthesia

Retrieved on: 
Monday, April 10, 2023
Health, Consumer, Surgery, Other Health, Dental, Pets, Veterinary, Blood pressure, Holter, University, Heart, VDS, Dog, Professional, Echocardiography, Veterinary dentistry, Blue Pearl, VMD, Exercise intolerance, Cough, Anesthesia, Journal of Veterinary Internal Medicine, University of Pennsylvania School of Veterinary Medicine, Patient, Risk, Cardiology, Pericardial effusion, Heart murmur, Abdomen, Electrocardiography, Diplomate of National Board, Heart rate, American College, Veterinary medicine, DVM, Anesthesiology, Cat, Dentistry, Medical imaging

Laurel, NJ, office of Veterinary Dentistry Specialists (VDS), a veterinary dentistry and oral surgery practice, has added board-certified veterinary cardiologist Megan King, VMD, DACVIM (Cardiology), to its roster of dental and anesthesia specialists.

Key Points: 
  • Laurel, NJ, office of Veterinary Dentistry Specialists (VDS), a veterinary dentistry and oral surgery practice, has added board-certified veterinary cardiologist Megan King, VMD, DACVIM (Cardiology), to its roster of dental and anesthesia specialists.
  • Adding comprehensive outpatient veterinary cardiology services makes VDS the first and only veterinary dentistry and oral surgery practice in the nation with anesthesiology and cardiology specialists available to care for each patient.
  • Cardiology services are also available for pet patients who do not need dentistry services.
  • She then earned Diplomate status by becoming board certified in veterinary cardiology by the American College of Veterinary Internal Medicine.

BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

Retrieved on: 
Wednesday, March 29, 2023
BCDA, DSMB, New Drug Application, Survival, Bone marrow, Allotransplantation, SAP, NK1R, Data monitoring committee, Medicare, Patient, Data, Substance P, American College, Therapy, Heart failure, Facial muscles, MSC, Bluerock Wildland Provincial Park, Security (finance), Myocardial injury after non-cardiac surgery, FDA, IND, III, Safety, Medical device, Centers for Medicare & Medicaid Services, Echocardiography, Cell therapy, Pharmaceuticals and Medical Devices Agency, Cell, Transplant, Research, CE, Quality of life, Form 10-K, COVID, Inflammation, Publication, Annual report, Pharmaceutical industry, Cryptocurrency, Helix, Heart

The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.

Key Points: 
  • The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.
  • This year holds the potential for catalysts that could dramatically improve our prospects, timetable, and attractiveness as a business.
  • Following the review, the DSMB indicated that it had no significant safety concerns and recommended that the study continue as designed.
  • After working with distinguished physician leaders, BioCardia expects to complete its formal submission for Japanese approval in the second quarter of 2023.

EC Healthcare Opened the First Organic Flagship Veterinary Hospital in Hong Kong

Retrieved on: 
Monday, March 6, 2023
Neurology, CFO, Echocardiography, Cat, Dog, Cardiology, Intensive care medicine, MRI, SEHK, CT, Pain, ICU, Growth, Health care, Management, Hospital

HONG KONG, Mar 6, 2023 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group opened its first organic flagship veterinary hospital, Animal Medical Academy Hospital (AMAH).

Key Points: 
  • HONG KONG, Mar 6, 2023 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group opened its first organic flagship veterinary hospital, Animal Medical Academy Hospital (AMAH).
  • Mr. Levin Lee, Executive Director and CFO of EC Healthcare said, "Since entering the veterinary business in 2021, EC Healthcare has been actively consolidating the market, and establish a leading brand.
  • Looking ahead, we look forward to collaborating with more veterinary talents to continuously expand the service scope, paving way for AMAH to become the leading flagship veterinary hospital in Hong Kong.
  • The Group will continue to invest in expanding its veterinary business in Hong Kong, building a renowned brand, and shaping the veterinary business to become a new growth engine for the Group."

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

Retrieved on: 
Monday, March 6, 2023
Assistant, III, Yale University, NYHA, Heart Failure Society of America, Therapy, Heart, LVEF, American College of Cardiology, Clinical trial, Echocardiography, Quality of life, Patient, BCDA, Johns Hopkins University, Heart failure, Phase, Site, Cardiology, FDA, American College, Doctor of Philosophy, Overalls, Medical imaging, Pharmaceutical industry

SUNNYVALE, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces that detailed echocardiography data from the roll-in cohort of the Phase III CardiAMP® Cell Therapy Heart Failure Trial is being presented today at the American College of Cardiology annual meeting by Peter Johnston, M.D., Assistant Professor of Medicine and Site Principal Investigator at Johns Hopkins University. The echocardiography results from baseline through one and two years showed a more than doubling in the number of heart segments functioning normally and restoration of function to 30 percent of previously non-functioning segments. This data expands upon data previously presented at the Heart Failure Society of America annual meeting last fall.

Key Points: 
  • This data expands upon data previously presented at the Heart Failure Society of America annual meeting last fall.
  • In completely non-functioning heart segments, 17 of 56, or 30 percent, of those heart segments resumed wall motion by two years.
  • In the previously presented data, patient demographics at study start demonstrated characteristics typical of the target population of NYHA class II and III ischemic heart failure patients with reduced ejection fraction.
  • “These early results lend further support to the potential efficacy of the autologous CardiAMP cell therapy and to our mission of restoring heart health,” said BioCardia CEO Peter Altman, PhD.

ConcertAI's TeraRecon, in Us2.AI Partnership, Integrates AI-Enabled Echocardiography Decision Support into Eureka Clinical AI Platform

Retrieved on: 
Friday, February 24, 2023
Death, Cardiology, Diagnosis, Artificial intelligence, Hospital, Partnership, Echo, Algorithm, FDA, Radiology, Patient, Prognosis, Neurology, PACS, Pulmonary hypertension, AI, Multi, 2D, Doppler effect, Deep learning, Echocardiography, Medical device

CAMBRIDGE, Mass., Feb. 24, 2023 /PRNewswire/ -- ConcertAI's TeraRecon Eureka Clinical AI SaaS platform brings artificial intelligence (AI) and Deep Learning technologies to fully automate a complete echocardiography or heart ultrasound report.  Us2.ai's FDA-cleared and CE Marked echocardiogram viewing and measurement tools can improve and speed the coordination-of-care for patients with suspected heart disease, the leading cause of death worldwide. 

Key Points: 
  • The Industry's leading AI SaaS solution for Acute Cardiac Care bringing critical patient insights to patients' care teams faster.
  • CAMBRIDGE, Mass., Feb. 24, 2023 /PRNewswire/ -- ConcertAI's TeraRecon Eureka Clinical AI SaaS platform brings artificial intelligence (AI) and Deep Learning technologies to fully automate a complete echocardiography or heart ultrasound report.
  • Using AI can dramatically reduce this time burden, as well as ensure a uniform standard of excellence in reporting.
  • Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more:

 Us2.ai to Deliver AI-Enabled Echocardiography Decision Support to Brigham and Women’s Hospital’s Cardiac Imaging Core Laboratory

Retrieved on: 
Thursday, February 23, 2023
Software, Research, General Health, Biometrics, Technology, Hospitals, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Other Science, Clinical trial, Death, Society, Heart, Cardiovascular disease, Patient, European Association for Cardio-Thoracic Surgery, AI, CW, Medtech, IHH Healthcare, Harvard Medical School, PW, Transthoracic echocardiogram, BWH, 2D, CE, Medical device, Medical imaging, Medicine, Echocardiography, Brigham, Doppler effect

Us2.ai’s software platform aims to improve the speed and scalability of the Cardiovascular Imaging Core Laboratory (CICL), part of the Brigham and Women’s Hospital (BWH) Division of Cardiovascular Medicine.

Key Points: 
  • Us2.ai’s software platform aims to improve the speed and scalability of the Cardiovascular Imaging Core Laboratory (CICL), part of the Brigham and Women’s Hospital (BWH) Division of Cardiovascular Medicine.
  • Echocardiography is an affordable, front-line tool used to diagnose and assess heart disease, but the process of acquiring, measuring, and analyzing the images is time-consuming.
  • “We validated this in our own laboratory, and it has proven comparable to human sonographers for a vast number of echocardiographic measures.
  • The fully automated cardiac measurements included in the software cover most standard measurements for adult transthoracic echocardiography recommended by the American and British Societies of Echocardiography and the European Association of Cardiovascular Imaging.

Sensydia Achieves Study Target for Heart-Sound AI

Retrieved on: 
Monday, February 6, 2023
Technology, Medical Devices, Hospitals, Health Technology, Cardiology, Practice Management, Biotechnology, Hardware, Health, Artificial Intelligence, Knowledge, Life, University of Pittsburgh Medical Center, Ronald Reagan, Diagnosis, Ronald Reagan UCLA Medical Center, Algorithm, Division, Patient, Harbor–UCLA Medical Center, Pulmonary hypertension, CPS, Artificial intelligence, University, Heart, Echocardiography, Risk, FDA, UPMC, Multimedia, Catheter, COVID-19, Heart failure, Cardiac output, MD, Medical device, Medical imaging, Pharmaceutical industry

Non-invasive cardiac assessment company Sensydia announced today that it has completed its 225-subject development study at the University of Pittsburgh Medical Center (UPMC).

Key Points: 
  • Non-invasive cardiac assessment company Sensydia announced today that it has completed its 225-subject development study at the University of Pittsburgh Medical Center (UPMC).
  • "When we began this study at UPMC during the height of the COVID-19 pandemic, our original enrollment target for the study was 110 subjects, but we ended up doubling that after hearing positive feedback from the UPMC study staff," said Anthony Arnold, President and CEO of Sensydia.
  • Sensydia plans to use data from this 225-subject study to develop the CPS pulmonary pressure algorithms.
  • In 2018, Sensydia received FDA 510(k) clearance for non-invasive measurement of ejection fraction by CPS, and in 2022, Sensydia CPS was granted Breakthrough Device Designation by the FDA.

Point-of-Care Ultrasound Training in Under-Resourced Region Improves Physician Knowledge

Retrieved on: 
Monday, February 13, 2023
Radiology, Health, RVT, Physician, Journal, POCUS, MBBS, RDMS, Safety, Mission, Textbook, Patient, PCA, Echocardiography, Physics, Knowledge, Education, MD, Nursing

ROCKVILLE, Md., Feb. 13, 2023 /PRNewswire/ -- A study published for the March 2023 issue of Journal of Radiology Nursing demonstrates that a short training course in Point-of-Care Ultrasound (POCUS) can measurably improve physician knowledge in under-resourced regions. The Mission POCUS in Haiti study focused on training and documenting the effectiveness of a short POCUS training course supported by the Point-of-Care Ultrasound Certification Academy (PCA), an education and certification arm of Inteleos, a non-profit global healthcare certification organization.

Key Points: 
  • ROCKVILLE, Md., Feb. 13, 2023 /PRNewswire/ -- A study published for the March 2023 issue of Journal of Radiology Nursing demonstrates that a short training course in Point-of-Care Ultrasound (POCUS) can measurably improve physician knowledge in under-resourced regions.
  • The intensive training included 24 hours of hands-on training and lectures with more than 100 patients scanned.
  • Of the 15 participants, 11 physicians showed improvement (by an average of 8%) in their test scores after training.
  • "We are encouraged by the results and will look for opportunities to replicate this type of training and expand it in other regions."